321 related articles for article (PubMed ID: 36187401)
1. Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows.
Costante F; Airola C; Santopaolo F; Gasbarrini A; Pompili M; Ponziani FR
World J Gastrointest Oncol; 2022 Sep; 14(9):1622-1636. PubMed ID: 36187401
[TBL] [Abstract][Full Text] [Related]
2. Clinico-histological and molecular features of hepatocellular carcinoma from nonalcoholic fatty liver disease.
Fujiwara N; Nakagawa H
Cancer Sci; 2023 Oct; 114(10):3825-3833. PubMed ID: 37545384
[TBL] [Abstract][Full Text] [Related]
3. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
4. Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients.
Huang S; Zhang J; Lai X; Zhuang L; Wu J
Front Mol Biosci; 2021; 8():781307. PubMed ID: 35004851
[No Abstract] [Full Text] [Related]
5. A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review.
Zaman CF; Sultana J; Dey P; Dutta J; Mustarin S; Tamanna N; Roy A; Bhowmick N; Khanam M; Sultana S; Chowdhury S; Khanam F; Sakibuzzaman M; Dutta P
Cureus; 2022 Sep; 14(9):e29657. PubMed ID: 36320966
[TBL] [Abstract][Full Text] [Related]
6. Tumor Necrosis Factor-Alpha and Adiponectin in Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma.
Vachliotis ID; Valsamidis I; Polyzos SA
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958479
[TBL] [Abstract][Full Text] [Related]
7. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.
Loomba R; Lim JK; Patton H; El-Serag HB
Gastroenterology; 2020 May; 158(6):1822-1830. PubMed ID: 32006545
[TBL] [Abstract][Full Text] [Related]
8. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma.
Chen C; Wang Z; Ding Y; Qin Y
Front Immunol; 2023; 14():1133308. PubMed ID: 36845131
[TBL] [Abstract][Full Text] [Related]
9. Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma.
Khan FZ; Perumpail RB; Wong RJ; Ahmed A
World J Hepatol; 2015 Aug; 7(18):2155-61. PubMed ID: 26328027
[TBL] [Abstract][Full Text] [Related]
10. The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma.
Zhang C; Yang M
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359642
[TBL] [Abstract][Full Text] [Related]
11. Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma.
Yoshikawa S; Taniguchi K; Sawamura H; Ikeda Y; Asai T; Tsuji A; Matsuda S
Explor Target Antitumor Ther; 2023; 4(4):556-568. PubMed ID: 37720344
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
13. Increase of α-dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer.
Petriv N; Neubert L; Vatashchuk M; Timrott K; Suo H; Hochnadel I; Huber R; Petzold C; Hrushchenko A; Yatsenko AS; Shcherbata HR; Wedemeyer H; Lichtinghagen R; Falfushynska H; Lushchak V; Manns MP; Bantel H; Semchyshyn H; Yevsa T
Oncoimmunology; 2021 Feb; 10(1):1874159. PubMed ID: 33628620
[TBL] [Abstract][Full Text] [Related]
14. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
15. Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma.
Yu Q; Wu L; Ji J; Feng J; Dai W; Li J; Wu J; Guo C
J Hepatocell Carcinoma; 2020; 7():271-288. PubMed ID: 33150145
[TBL] [Abstract][Full Text] [Related]
16. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
[TBL] [Abstract][Full Text] [Related]
17. The Global Prevalence of Nonalcoholic Fatty Liver Disease and its Association With Cancers: Systematic Review and Meta-Analysis.
Muhamad NA; Maamor NH; Leman FN; Mohamad ZA; Bakon SK; Abdul Mutalip MH; Rosli IA; Aris T; Lai NM; Abu Hassan MR
Interact J Med Res; 2023 Jul; 12():e40653. PubMed ID: 37467012
[TBL] [Abstract][Full Text] [Related]
18. Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.
Chen J; Song S; Li X; Bian D; Wu X
Saudi J Gastroenterol; 2022; 28(2):92-100. PubMed ID: 34810377
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle.
Sukowati C; Cabral LKD; Tiribelli C
Ann Hepatol; 2022; 27(5):100740. PubMed ID: 35809835
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.
Petrelli F; Manara M; Colombo S; De Santi G; Ghidini M; Mariani M; Iaculli A; Rausa E; Rampulla V; Arru M; Viti M; Lonati V; Ghidini A; Luciani A; Facciorusso A
Neoplasia; 2022 Aug; 30():100809. PubMed ID: 35636146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
